Objective To compare the anesthetic effectiveness and safety of remimazolam and propofol in painless induced abortion. Methods A total of 100 patients who underwent painless induced abortion in the Second People's Hospital of Heifei from June 2020 to September 2020 were selected. According to the random number table method, they were divided into two groups (n=50): a propofol group (group B) and a ramazolam group (group R). Patients in group B were anesthetized with propofol combined with sufentanil, while those in group R were anesthetized with remimazolam combined with sufentanil. Both groups were compared for the mean artery pressure (MAP), heart rate, and pulse oxygen saturation (SpO2) before anesthesia induction (T1), after disappearance of the eyelash reflex (T2), at postoperative 1 min (T3), at the end of operation (T4), and after emergence from anesthesia (T5). Furthermore, both groups were compared for the onset time of anesthesia, the time of consciousness recovery, the time of awakening, the time of discharge and related complications (body movement, circulatory inhibition, respiratory inhibition, injection pain, hiccup, and vomiting during operation). Results Compared with those at T1, group B showed decreases in MAP, heart rate, and SpO2 at T2 (P<0.05), while only reduction in MAP was seen in group R at T2 (P<0.05). Compared with group B, group P presented increased MAP and SpO2 at T2 (P<0.05), increased heart rate and SpO2 at T3 (P<0.05), increased heart rate at T4 and T5 (P<0.05); increases in the onset time of anesthesia, the time of consciousness recovery, and the time of awakening (P<0.05); and decreases in the incidences of respiratory depression, circulatory depression, and injection pain (P<0.05), but increases in the incidences of hiccups and vomiting (P<0.05). There was no statistical difference in other indicators between the two groups (P>0.05). Conclusions Propofol and remimazolam combined with sufentanil are safe and effective for painless induced abortion. Treatment with propofol group results in obvious respiratory inhibition and circulatory inhibition, with a high incidence of injection pain. Those receiving remazolam show stable vital signs, but the incidences of hiccup and vomiting are high.